Crossmark

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

Crossref DOI link: https://doi.org/10.1186/s13756-020-00799-2

Published Online: 2020-08-26

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fokam, Joseph https://orcid.org/0000-0002-1501-2763
Takou, Desire

Semengue, Ezechiel Ngoufack Jagni

Teto, Georges

Beloumou, Grace

Dambaya, Beatrice

Santoro, Maria-Mercedes

Mossiang, Leonella

Billong, Serge Clotaire

Cham, Fatim

Sosso, Samuel Martin

Temgoua, Edith Saounde

Nanfack, Aubin Joseph

Moudourou, Sylvie

Kamgaing, Nelly

Kamgaing, Rachel

Ngako Pamen, Joelle Nounouce

Etame, Mireille Mpoudi Ngole

Bissek, Anne-Cecile Z.-K.

Elat, Jean-Bosco N.

Moussi, Emmanuel Eben

Colizzi, Vittorio

Perno, Carlo-Federico

Ndjolo, Alexis

,
Funding

Funding for this research was provided by:

Chantal Biya International Reference center for research on HIV/AIDS prevention and management
License Information

Text and Data Mining valid from 2020-08-26

Version of Record valid from 2020-08-26
More Information

Article History

Received: 25 March 2020

Accepted: 6 August 2020

First Online: 26 August 2020

Ethics approval and consent to participate

: Administrative authorisation was provided by the Directorate General of the Chantal BIYA International Reference for research on HIV/AIDS prevention and management (CIRCB), under the reference number 0191/019/CIRCB/DG/SAA/BRH. Ethical clearance was obtained from the National Ethics Committee for Research on Human Health (reference number 2019/06/34/CE/CNERSH/SP of June 14, 2019). Written informed consent was provided.

: Consent has been provided by the patient.

: The authors declare they have no personal relationship(s) or financial interests that may have influenced the writing of this report.

Document is current

Any future updates will be listed below